Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement

Programmed death-ligand 1 (PD-L1) expression is a predictor of immune checkpoint inhibitor (ICI) treatment efficacy. The clinical efficacy of ICIs for non-small-cell lung cancer (NSCLC) patients harboring major mutations, such as EGFR or ALK mutations, is limited. We genotyped 190 patients with adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Oya, Yuko, Kuroda, Hiroaki, Nakada, Takeo, Takahashi, Yusuke, Sakakura, Noriaki, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178012/
https://www.ncbi.nlm.nih.gov/pubmed/32283823
http://dx.doi.org/10.3390/ijms21072623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178012/
https://www.ncbi.nlm.nih.gov/pubmed/32283823
http://dx.doi.org/10.3390/ijms21072623

Ejemplares similares